Dainippon Sumitomo Pharma Overview

  • Founded
  • 1897
Founded
  • Status
  • Public
  • Employees
  • 6,822
Employees
  • Stock Symbol
  • 4506
Stock Symbol
  • Investments
  • 20
  • Share Price
  • $11.68
  • (As of Wednesday Closing)

Dainippon Sumitomo Pharma General Information

Description

Sumitomo Dainippon Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Formerly Known As
Dainippon Pharma
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Food Products
Other Industries
Pharmaceuticals
Other Healthcare
Stock Exchange
TKS
Primary Office
  • 6-8 Doshomachi 2-chome
  • Chuo-ku
  • Osaka, 541-0045
  • Japan
+81 00-0000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Dainippon Sumitomo Pharma Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.68 $11.99 $11.43 - $21.57 $4.76B 397M 1.14M $1.30

Dainippon Sumitomo Pharma Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020 FY 2019 31-Mar-2019
EV 8,498,197 8,499,539 6,743,443 8,700,412
Revenue 5,099,302 4,865,659 4,439,630 4,142,275
EBITDA 953,705 885,491 925,243 648,128
Net Income 515,080 530,170 374,801 438,582
Total Assets 11,321,708 11,858,040 11,626,709 7,528,146
Total Debt 2,415,617 2,482,142 2,757,209 279,042
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Dainippon Sumitomo Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dainippon Sumitomo Pharma‘s full profile, request access.

Request a free trial

Dainippon Sumitomo Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Sumitomo Dainippon Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sale
Food Products
Osaka, Japan
6,822 As of 2021
00000000

000000 0

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla p
0000 000000000
Tokyo, Japan
00000 As of 0000
00.000
00000000 00.000

0000000

onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
00000000 00000000
New Brunswick, NJ
000000 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dainippon Sumitomo Pharma Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Otsuka Holdings Corporation Tokyo, Japan 00000 00.000 00000000 00.000
0000000 & 0000000 Corporation New Brunswick, NJ 000000 00000000
0000000000 000000 Corporation Doshomachi, Japan 0000
00000000 Formerly VC-backed Dublin, Ireland 0000 00.000 000000000 00.000
To view Dainippon Sumitomo Pharma’s complete competitors history, request access »

Dainippon Sumitomo Pharma Patents

Dainippon Sumitomo Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210338852-A1 Ri-labeled humanized antibody Pending 18-Oct-2019 00000000000
US-10758535-B1 Therapeutic drug for dyskinesia Active 26-Apr-2019 0000000000
US-20210060015-A1 Therapeutic drug for dyskinesia Pending 26-Apr-2019 0000000000
US-20210338170-A1 Method, device, and program for assessing relevance of respective preventive interventional actions to health in health domain of interest Pending 12-Oct-2018 0000000000
EP-3866172-A1 Method, device, and program for assessing relevance of respective preventive interventional actions to health in health domain of interest Pending 12-Oct-2018 A61B5/7246
To view Dainippon Sumitomo Pharma’s complete patent history, request access »

Dainippon Sumitomo Pharma Executive Team (9)

Name Title Board Seat Contact Info
Hiroshi Nomura Representative Director, President & Chief Executive Officer
Hiroyuki Baba Senior Executive Officer
Shigeyuki Nishinaka Executive Officer
You’re viewing 3 of 9 executive team members. Get the full list »

Dainippon Sumitomo Pharma Board Members (3)

Name Representing Role Since
000000 0000 Dainippon Sumitomo Pharma Representative Director and Chairman 000 0000
You’re viewing 1 of 3 board members. Get the full list »

Dainippon Sumitomo Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dainippon Sumitomo Pharma Investments & Acquisitions (20)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 30-Sep-2021 0000 00000 Biotechnology
0000000 00000 23-Mar-2021 000000000 00000 Biotechnology 000000000
0000000000 00 26-Oct-2020 00000 0000 0000 Diagnostic Equipment 00000000
0000000 00000 03-Jan-2020 000000000 000 Biotechnology 0000000 0
Altavant Sciences 30-Dec-2019 Merger/Acquisition Drug Discovery
You’re viewing 5 of 20 investments and acquisitions. Get the full list »

Dainippon Sumitomo Pharma Subsidiaries (6)

Company Name Industry Location Founded
Altavant Sciences Drug Discovery Cary, NC 2018
00000000 00000000 Biotechnology Cambridge, MA 0000
0000000 00000000 Biotechnology Brisbane, CA 0000
0000000 00000000 Biotechnology Irvine, CA 0000
000000000 00000000 Biotechnology Philadelphia, PA 0000
You’re viewing 5 of 6 subsidiaries. Get the full list »

Dainippon Sumitomo Pharma Exits (6)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000000 000000 26-Oct-2020 00000 00000 00 0000 Completed
  • 3 buyers
0000000000 000000 24-Jul-2019 00000 00000 00 000 Completed
  • 5 buyers
000000 0000000 22-May-2014 00000 00000 00 00.000 Completed
  • 3 buyers
00000000000 000000 27-Mar-2014 00000 00000 00 0000 Completed
  • 000000000 00000000
Create Vaccine 31-Jul-2013 Joint Venture Completed
  • 2 buyers
You’re viewing 5 of 6 exits. Get the full list »